Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma

Enrico Battolla, Pier Aldo Canessa, Paola Ferro, Maria Cristiana Franceschini, Vincenzo Fontana, Paolo Dessanti, Valentina Pinelli, Anna Morabito, Franco Fedeli, Maria Pia Pistillo, Silvio Roncella

Research output: Contribution to journalArticle

Abstract

Background: In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). Therefore we compared the diagnostic performance of FBLN3 against that of soluble mesothelinrelated peptide (SMRP) in a cohort of Italian patients. Materials and Methods: FBLN3 and SMRP were detected in PE from 33 patients with MPM, 64 with pleural benign lesions and 23 with non-MPM pleural metastases using a commercial enzyme-linked-immunosorbent(ELISA)-assay kit according to manufacturers' instructions. Results: Levels of FBLN3 were similar in PE from MPM and PE from other pathologies (geometric mean=68.1 vs. 66.2 ng/ml; p=0.872) in contrast to SMRP levels, which were significantly higher in PE from MPM (geometric mean=14.6 vs. 3.2 nM; p<0.001). Receiver operating characteristic analysis confirmed that SMRP showed a good performance (area under the curve=0.79, p<0.001), whereas FBLN3 was not able to discriminate MPM from other pathologies (area under the curve=0.44, p=0.838). Conclusion: FBLN3 detection in PE, in contrast to SMRP detection, is not useful as a biomarker for the diagnosis of PE from MPM.

Original languageEnglish
Pages (from-to)1387-1391
Number of pages5
JournalAnticancer Research
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Keywords

  • Fibulin-3
  • Malignant pleural mesothelioma
  • Mesothelin
  • Pleural effusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma'. Together they form a unique fingerprint.

  • Cite this

    Battolla, E., Canessa, P. A., Ferro, P., Franceschini, M. C., Fontana, V., Dessanti, P., Pinelli, V., Morabito, A., Fedeli, F., Pistillo, M. P., & Roncella, S. (2017). Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma. Anticancer Research, 37(3), 1387-1391. https://doi.org/10.21873/anticanres.11460